We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+24.5%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$498M
AUM Growth
+$258M
Cap. Flow
+$47.7M
Cap. Flow %
9.58%
Top 10 Hldgs %
69.52%
Holding
145
New
57
Increased
20
Reduced
22
Closed
41

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$31.2M
2
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$6.99M
3
MRNA icon
Moderna
MRNA
+$3.94M
4
XERS icon
Xeris Biopharma Holdings
XERS
+$3.78M
5
MTVA
MetaVia Inc
MTVA
+$3.18M

Top Sells

Rank Stock Value
1
GLD icon
SPDR Gold Trust
GLD
+$2.89M
2
ENLV icon
Enlivex Ltd
ENLV
+$2.31M
3
NOVN
Novan, Inc. Common Stock
NOVN
+$2.11M
4
OTLK icon
Outlook Therapeutics
OTLK
+$1.94M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$1.78M

Sector Composition

Rank Sector Weight
1 Miscellaneous 87.38%
2 Healthcare 11.46%
3 Materials 0.58%
4 Industrials 0.26%
5 Technology 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RKDA icon
76
Arcadia Biosciences
RKDA
$1.03M
$224K 0.05%
+1,490
New +$232K
ALT icon
77
CALL
Altimmune
ALT
$632M
$202K 0.04%
+189
New +$1.04K
BXRX
78
PUT
DELISTED
Baudax Bio, Inc. Common Stock
BXRX
– –
0
– –
RKTO
79
Rocket One Inc
RKTO
$18M
$177K 0.04%
+2,747
New +$215K
XWEL icon
80
PUT
XWELL
XWEL
$8.02M
$141K 0.03%
+17
New +$893
MDGSW
81
DELISTED
Medigus Ltd. Series C Warrant
MDGSW
$123K 0.02%
585,859
-421,585
-42% -$145K
MARK
82
PUT
DELISTED
Remark Holdings, Inc.
MARK
$97K 0.02%
+41
New +$631
BNTC icon
83
Benitec Biopharma
BNTC
$408M
$94K 0.02%
698
-149
-18% -$20.1K
EFOI icon
84
PUT
Energy Focus
EFOI
$17.8M
$83K 0.02%
+17
New +$434
PALI icon
85
Palisade Bio
PALI
$354M
$83K 0.02%
26
– –
MARK
86
DELISTED
Remark Holdings, Inc.
MARK
$80K 0.02%
+3,395
New +$52.2K
RDGT
87
Ridgetech Inc
RDGT
$3.04M
$69K 0.01%
+1
New +$76K
ATXS
88
CALL
DELISTED
Astria Therapeutics
ATXS
$65K 0.01%
+17
New +$605
ENLV icon
89
Enlivex Ltd
ENLV
$15.7M
$65K 0.01%
862
-28,850
-97% -$2.31M
IMNN icon
90
PUT
Imunon
IMNN
$8.08M
$54K 0.01%
+1
New +$434
INO icon
91
Inovio Pharmaceuticals
INO
$120M
$54K 0.01%
+167
New +$26.8K
ASXC
92
PUT
DELISTED
Asensus Surgical, Inc.
ASXC
$43K 0.01%
+794
New +$383
TEUM
93
DELISTED
Pareteum Corporation
TEUM
$35K 0.01%
56,757
-515,514
-90% -$284K
PWCM
94
PowerCompute Inc
PWCM
$1.76M
$34K 0.01%
+33
New +$22.5K
LFWD icon
95
ReWalk Robotics
LFWD
$20.8M
$34K 0.01%
227
-2,508
-92% -$262K
PTE
96
PUT
DELISTED
PolarityTE, Inc. Common Stock
PTE
$25K 0.01%
+8
New +$213
NSPR icon
97
InspireMD
NSPR
$37.9M
$22K ﹤0.01%
3,220
+2,484
+338% +$25.2K
PULM icon
98
Pulmatrix
PULM
$5.3M
$21K ﹤0.01%
+597
New +$18.9K
LPCN icon
99
Lipocine
LPCN
$18.2M
$18K ﹤0.01%
+850
New +$11K
LPCN icon
100
PUT
Lipocine
LPCN
$18.2M
$13K ﹤0.01%
+6
New +$78
2 3
4
5 6

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q2 2020 Portfolio in Review

As of Q2 2020, Sabby Management held 145 positions worth $498M, up 107% from $241M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Sabby Management deployed $47.7M of net new capital in Q2 2020, opening 57 new positions and adding to 20 existing holdings. Its largest new stake was Biogen: 103,902 shares worth $27.8M.

By sector, the portfolio is most concentrated in Miscellaneous at 87% of assets, down from 91% a quarter earlier, followed by Healthcare and Materials.

On the sell side, the largest reduction was Enlivex Ltd, an estimated $2.31M trimmed.

  • Sabby Management's largest Q2 2020 buy was Biogen: 103,902 shares worth $27.8M.
  • Sabby Management added most to State Street Health Care Select Sector SPDR ETF in Q2 2020, an estimated $6.99M increase.
  • Sabby Management's biggest Q2 2020 reduction was Enlivex Ltd, cutting an estimated $2.31M.
  • Sabby Management fully exited SPDR Gold Trust in Q2 2020, selling an estimated $2.89M.
  • Sabby Management's ten largest holdings make up 70% of its $498M portfolio in Q2 2020.
  • Sabby Management opened 57 new positions and closed 41 in Q2 2020.
  • Sabby Management's portfolio value rose 107% quarter-over-quarter to $498M.

Based on Sabby Management's 13F filing for Q2 2020, filed 14 Aug 2020.